Acute toxicity after CyberKnife-delivered hypofractionated radiotherapy for treatment of prostate cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 1, 2011, Pages 6-10

  Townsend, Natasa C ^a   Huth, Bradley J ^a   Ding, William ^a   Garber, Bruce ^a   Mooreville, Michael ^b   Arrigo, Stephen ^c,d   Lamond, John ^c,d   Brady, Luther W ^a,c  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b Urology Care Center   (United States)

^c Philadelphia CyberKnife Center   (United States)

^d CROZER CHESTER MEDICAL CENTER   (United States)

Author keywords

acute toxicity; hypofractionation; prostate cancer; stereotactic body radiation therapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CYBERKNIFE; CYBERKNIFE DELIVERED HYPOFRACTIONATED RADIOTHERAPY; DIARRHEA; DYSURIA; EARLY CANCER; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HUMAN; IMPAIRED BLADDER EMPTYING; INTENSITY MODULATED RADIATION THERAPY; MALE; MEDICAL RECORD REVIEW; NOCTURIA; PATIENT SAFETY; PROSTATE ADENOCARCINOMA; PROTEIN BLOOD LEVEL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIATION SAFETY; RETROSPECTIVE STUDY; TOMOTHERAPY; URINARY FREQUENCY; URINE INCONTINENCE; URINE RETENTION; UROGENITAL TRACT DISEASE;

AGED; AGED, 80 AND OVER; DOSE FRACTIONATION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOSURGERY; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; URINATION DISORDERS;

EID: 79951642431     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181c4c7c4     Document Type: Article

References (22)

1. National Cancer Institute. Cancer Topics. http://www.cancer.gov/ cancertopics/types/prostate. Accessed April 6, 2009.
2. Brenner DJ, Martinez AA, Edmundson GK, et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 2002;52:6-13. (Pubitemid 34041562)
3. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:1095-1101. (Pubitemid 29144800)
4. Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys. 2001;50:1021-1031. (Pubitemid 32594841)
5. Collins CD, Lloyd-Davies RW, Swan AV. Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique. Clin Oncol (R Coll Radiol). 1991;3:127-132.
6. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarci-noma of the prostate: a randomized controlled trial. JAMA. 2005;294:1233-1239. (Pubitemid 41352111)
7. Peeters ST, Heemsbergen WD, van Putten WL, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys. 2005;61:1019-1034. (Pubitemid 40340897)
8. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002;53:1111-1116. (Pubitemid 34787844)
9. De Meerleer G, Vakaet L, Meersschout S, et al. Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys. 2004;60:777-787. (Pubitemid 39311757)
10. Lim TS, Cheung Patrick CF, et al. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results. Int J Radiat Oncol Biol Phys. 2008;72:85-92.
11. Livsey JE, Cowan RA, Wylie JP, et al. Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis. Int J Radiat Oncol Biol Phys. 2003;57:1254-1259. (Pubitemid 37443962)
12. Kupelian PA, Thakkar VV, Khuntia D, et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys. 2005;63:1463-1468. (Pubitemid 41628043)
13. Pollack A, Hanlon AL, Horwitz EM, et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys. 2006; 64:518-526. (Pubitemid 43083441)
14. Demanes DJ, Rodriguez RR, Schour L, et al. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys. 2005;61:1306-1316. (Pubitemid 40470411)
15. Vargas CE, Martinez AA, Boike TP, et al. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study. Int J Radiat Oncol Biol Phys. 2006;66:416-423. (Pubitemid 44332728)
16. Fuller DB, Naitoh J, Lee C, et al. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachyther-apy and preliminary clinical observations. Int J Radiat Oncol Biol Phys. 2008;70:1588-1597. (Pubitemid 351417778)
17. Common Terminology Criteria for Adverse Events, Version 3.0. US National Institutes of Health; National Cancer Institute; Division of Cancer Treatment and Diagnosis: Cancer Therapy Evaluation Program. Available at: http:// ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf. Accessed March 12, 2009.
18. Michalski JM, Winter K, Purdy JA, et al. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose level V. Int J Radiat Oncol Biol Phys 2005;62:706-713. (Pubitemid 40779758)
19. Yoshioka Y, Nose T, Yoshida K, et al. High-dose-rate brachytherapy as monotherapy for localized prostate cancer: a retrospective analysis with special focus on tolerance and chronic toxicity. Int J Radiat Oncol Biol Phys. 2003;56:213-220. (Pubitemid 36403694)
20. Corner C, Rojas AM, Bryant L, et al. A Phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72:441-446.
21. Madsen BL, Hsi RA, Pham HT, et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys. 2007;67: 1099-1105.
22. King CR, Brooks JD, Gill H, et al. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys. 2009;73:1043-1048.